Medicore, Inc. Reports Second Quarter 2005 Results


HIALEAH, Fla., Aug. 15, 2005 (PRIMEZONE) -- Medicore, Inc. (Nasdaq:MDKI) announced financial results for the first half of 2005. Operating revenues for the second quarter of 2005 increased 16% to $11,339,000 compared to $9,788,000 for the same period last year. Operating revenues for the first half of 2005 increased 19% to $22,148,000 compared to $18,639,000 for the same period last year.

Net income was $4,000 or $.00 per share ($.00 diluted) for the second quarter of 2005 compared to a net loss of $(34,000) or $(.00) per share ($(.01) diluted) for the same period last year. There was a net loss of $(62,000) or ($.01) per share ($(.01) diluted) for the first half of 2005 compared to a net loss of $(34,000) or $(.00) per share ($(.01) diluted for the same period last year. First half 2005 results include $242,000 of costs associated with our pending merger with DCA. The first half of 2004 included a $339,000 net of tax gain resulting from a sale of a former subsidiary.

Thomas K. Langbein, Chief Executive Officer and President, commented, "While our majority-owned subsidiary, Dialysis Corporation of America ("DCA"), has experienced reimbursement pressure from its payors and the costs associated with the opening of new centers, the growth and financial performance of DCA continues to be healthy. DCA's operating revenues increased 16% and net income increased 14% for the quarter compared to the same period last year. DCA achieved a 19% increase in operating revenues during the first half of 2005 compared to the same period last year and experienced a $93,000 increase in net income during the first half of 2005 compared to the same period last year in spite of incurring $100,000 in costs associated with the pending merger of our company with DCA, and pre-operating costs of six new dialysis centers under development. We expect additional growth to result from DCA's ongoing negotiations regarding new development opportunities."

The company is primarily engaged in the operation of kidney dialysis centers through DCA, which owns or manages 23 operating free-standing kidney hemodialysis centers in Georgia, Maryland, New Jersey, Ohio, Pennsylvania, South Carolina and Virginia providing patients with a full range of quality in-center, and at-home dialysis services, as well as providing in-hospital services in many of its markets. DCA has six new dialysis centers under development in Maryland, Ohio, Pennsylvania and South Carolina. The company also distributes medical products and has investments in two affiliated Linux software companies.

This release contains forward-looking statements that are subject to risks and uncertainties that could affect the business and prospects of the company and cause actual results and plans to differ materially from those anticipated. Those factors include, but are not limited to, general economic conditions, certain delays beyond the company's control with respect to future business events, DCA's ability to maintain continued growth, receipt of shareholder approval relating to the merger of our company with DCA, the likelihood of realizing the company's investments in the two affiliated Linux software companies, the ability of DCA to timely develop or acquire additional dialysis facilities, whether patient bases of certain of DCA's facilities can mature to provide profitability, regulation of dialysis operations, government rate determination for Medicare reimbursement, the highly competitive environment in the operation, development and acquisition of dialysis centers and other risks detailed in the company's filings with the Securities and Exchange Commission, particularly as described in the company's annual report on Form 10-K/A1 for the year ended December 31, 2004. The historical results contained in this press release are not necessarily indicative of future performance of the company.

Other Medicore, Inc. press releases, corporate governance material, quarterly and current reports, and the most recent annual report on Form 10-K/A1 for the year ended December 31, 2004, and other filings with the Securities and Exchange Commission are available through Medicore's internet home page: http://www.medicore.com.



                MEDICORE, INC. AND SUBSIDIARIES

               CONSOLIDATED STATEMENTS OF OPERATIONS

                  Three Months Ended          Six Months Ended
                        June 30,                   June 30,
                   ----------------------    ----------------------
                      2005         2004           2005         2004
                  ----------   ----------    ----------   ----------
 Revenues:
  Sales:
   Product sales $  197,301  $    198,828  $   393,996   $     423,146
   Medical
    service
    revenues      11,021,524    9,496,608    21,505,625     17,906,132
                 ---------- ------------  ------------   ------------
   Total sales    11,218,825    9,695,436    21,899,621     18,329,278
     Other income    119,902       92,610       248,297        309,655
                 ----------- ------------  ------------   ------------
                  11,338,727    9,788,046    22,147,918     18,638,933
                 ----------- ------------  ------------   ------------
 Cost and expenses
  Cost of sales:
  Cost of product
   sales             124,037      131,623       230,330        249,250
   Cost of
    medical
    services       6,724,869    5,738,179    13,267,470     10,900,401
                  ----------  ------------ ------------   ------------
   Total cost of
    sales          6,848,906    5,869,802    13,497,800     11,149,651
   Legal fees
    related party     90,000       90,000       179,000        169,000
  Selling,
   general
   and
   administrative
   expenses        3,861,744    3,196,226     7,463,455      6,794,501
   Provision for
    doubtful
    accounts         204,649      200,042       452,643        348,337
                  ----------  ------------ ------------   ------------
                  11,005,299    9,356,070    21,592,898     18,461,489
                  ----------  ------------ ------------   ------------

 Operating income    333,428      431,976       555,020        177,444

  Other income:
  Interest
   income
   related
   parties             1,421          960         2,713          4,785
  Other income,
    net              170,409       78,325       276,776        153,623
                  ---------- -----------   ------------   ------------
                     171,830       79,285       279,489        158,408
                  ----------- ------------ ------------   ------------

  Income from
   continuing
   operations
   before income
   taxes,
   minority
   interest and
   equity in
   affiliate
   earnings          505,258      511,261       834,509        335,852
 
 Income tax
  provision          310,105      277,665       618,908        286,773
                  ----------- ------------ ------------   ------------
 Income from
  continuing
  operations
  before
  minority
  interest
  and equity in
  affiliate
  earnings           195,153      233,596       215,601         49,079

 Minority interest
  in income of
  consolidated
  subsidiaries      (285,908)    (298,568)    (492,045)      (472,491)

 Equity in
  affiliate
  earnings            94,689       31,362      214,798          50,395
                  ---------- ------------  ------------   ------------
 Income (loss)
  from continuing
  operations           3,934   $  (33,610)     (61,646)  $    (373,017)

 Discontinued
  operations:
 Gain on disposal
  of electro-
  mechanical
  manufacturing
  operation, net
  of applicable
  income taxes of
  $207,000              --            --            --         338,995
                 ---------- ------------  ------------    ------------

 Net income
  (loss)             3,934       (33,610)      (61,646)  $    (34,022)
                 ==========  ============ ============    ============

 Income (loss) per
  share:
  Basic          $       --   $       --         (.01)   $        --
                 ==========  ============ ============    ============
  Diluted        $       --   $     (.01)        (.01)   $      (.01)
                 ==========  ============ ============    ============


            

Contact Data